<DOC>
	<DOCNO>NCT00850642</DOCNO>
	<brief_summary>A randomised , double-blind , placebo-controlled , parallel group study evaluate effect treatment GSK2190915 , FLAP inhibitor , add-on current inhale corticosteroid therapy patient moderate severe asthma elevate sputum neutrophil .</brief_summary>
	<brief_title>GSK2190915 Moderate Severe Asthma Study</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>A subject eligible inclusion study follow criterion apply : Males female age 18 65 year inclusive . Body mass index within range 18.537.0 kilograms/metre2 ( kg/m2 ) . An established clinical history Asthma accordance definition GINA Guidelines [ GINA , 2006 ] . Subjects screen within last year document reversibility ( &gt; 12 % ) short act bronchodilator , positive methacholine challenge , positive histamine challenge ( PC20 &lt; 8mg/ml ) . A female subject eligible participate : nonchildbearing potential define premenopausal female document ( medical report verification ) hysterectomy double oophrectomy postmenopausal define 12 month spontaneous amenorrhea 6 month spontaneous amenorrhea serum FSH level &gt; 40 mIU/mL estradiol &lt; 40 pg/ml ( &lt; 140 pmol/L ) 6 week postsurgical bilateral oophorectomy without hysterectomy ; childbearing potential agrees use one contracception method list Section 8.1 appropriate period time prior start dose 3 month last dose . Male subject must agree use one contraception method list Section 8.1 . This criterion must follow time first dose study medication 3 month last dose . Subject moderate severe asthma force expiratory volume one second ( FEV1 ) ≥ 50 % predict . Subject regular inhaled corticosteroid without combination regular long act Beta 2 Agonist . The dose stable least 4 week screen . Subjects take minimum FP 250mg BID equivalent . Persistent sputum neutrophilia define sputum neutrophil ≥ 65 % TTC &lt; 15 million cells/g evidence eosinophilia ( sputum eosinophil &lt; 2 % ) . Persistent define criterion meet screening ( within 6 month precede screen ) visit 1 . Signed date write informed consent obtain subject The subject able understand comply protocol requirement , instruction protocolstated restriction . A subject eligible inclusion study follow criterion apply : Past present disease , judge investigator medical monitor , may affect outcome study . These disease include , limited , cardiovascular disease , malignancy , gastrointestinal disease , hepatic disease , renal disease , haematological disease , neurological disease , endocrine disease pulmonary disease ( exclude asthma include confine chronic bronchitis , emphysema , bronchiectasis , eosinophilic bronchitis pulmonary fibrosis ) . Clinically significant abnormality safety laboratory analysis screening . Subject uncontrolled hypertension hypertensive screening . Hypertension screen define persistent systolic BP &gt; 150 mmHg diastolic BP &gt; 90mmHg . History asthma exacerbation acute intercurrent respiratory illness ( viral respiratory syndrome , bronchitis , pneumonia ) four week period screen visit History lifethreatening asthma , define asthma episode require intubation and/or associate hypercapnoea , respiratory arrest and/or hypoxic seizure . Subject unable abstain take prescription nonprescription drug ( include vitamin dietary herbal supplement ) include nonsteroidal antiinflammatory drug ( NSAIDs ) , antidepressant drug , antihistamine antiasthma , antirhinitis hay fever medication , exception ICS , LABA short action beta agonist , 14 day screen followup visit unless opinion Investigator sponsor medication interfere study Administration oral injectable steroid within 6 week screen . The subject participate study new molecular entity previous 3 month participate 4 clinical study previous 12 month prior first dose day . Administration anti leukotrienne therapy 14 day screen study . Administration vaccination within 1 month screening study . Administration biological therapy within 3 month screen visit study Subject undergo allergen desensitisation therapy . Administration OATP1B1 substrates 2 week dose , followup assessment complete . There risk noncompliance study procedure . History blood donation ( 500 mL ) within 3 month start clinical study . The subject regularly drink 28 unit alcohol week male , 21 unit per week female . One unit alcohol define medium ( 125 ml ) glass wine , half pint ( 250 ml ) beer one measure ( 25 ml ) spirit . The subject screening QTc value &gt; 450msec , PR interval outside range 120 220msec ECG suitable QT measurement ( e.g . poorly define termination Twave ) . The subject test positive hepatitis C antibody hepatitis B surface antigen . The subject test positive HIV antibody . The subject positive prestudy urine drug urine breath alcohol screen . A minimum list drug screen include Amphetamines , Barbituates , Cocaine , Opiates , Cannabinoids Benzodiazepines .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Sputum cell count</keyword>
	<keyword>Neutrophils</keyword>
	<keyword>Severe Asthma</keyword>
	<keyword>ICS</keyword>
	<keyword>Inhaled corticosteroid</keyword>
</DOC>